Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1486 to 1500 of 2182 results for guidelines

  1. ENDURALIFE powered CRT-D devices for treating heart failure (HTG433)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

    HealthTech guidance
    Last updated
    21 July 2021
    View recommendations

    Sections for HTG433

  2. Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)

    Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.

    HealthTech guidance
    Published
    13 November 2025
    View recommendations

    Sections for HTG763

  3. Designing systems for documenting drug allergy:- Which documentation strategies would be most clinically and cost effective to minimise the number of people who are re-exposed to drugs to which they have a suspected or confirmed allergy, looking in particular at: - electronic health records that include features specifically designed to record and alert clinicians to drug allergy information, compared with systems without such features and - different formats for patient-held, structured drug allergy documentation?

    incidents have caused harm or death. The systematic review undertaken for this guideline identified a wide range of documentation...

    Research recommendation
    Published
    9 June 2015

  4. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

    Technology appraisal guidance
    Last updated
    18 November 2020
    View recommendations

    Sections for TA152

  5. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  6. Zio XT for detecting cardiac arrhythmias (HTG562)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

    HealthTech guidance
    Published
    1 December 2020
    View recommendations

    Sections for HTG562

  7. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    21 September 2022

  8. Oral antibiotic challenge for diagnosing antibiotic allergy in children:- In children who have a suspected allergy to an antibiotic, is it clinically and cost effective to proceed directly (without prior skin or intradermal tests) to a diagnostic oral antibiotic challenge rather than referring them to specialist drug allergy services?

    diagnosed with an antibiotic allergy. The evidence review for this clinical guideline found no evidence to support the reliability of...

    Research recommendation
    Published
    9 June 2015

  9. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 March 2017

  10. Referral criteria for people with suspected axial spondyloarthritis:- What are the optimal referral criteria for people with suspected axial spondyloarthritis?

    quality-adjusted life year (QALY) gained (the NICE economic model developed for this guideline could easily be used to estimate...

    Research recommendation
    Published
    4 May 2017

  11. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    15 June 2021
    View recommendations

    Sections for TA707

  12. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    15 November 2017
    View recommendations

    Sections for TA488

  13. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  14. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  15. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued